http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111321125-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16121 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5254 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16122 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-44 |
| filingDate | 2020-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111321125-B |
| titleOfInvention | Recombinant influenza virus and its application in vaccine |
| abstract | The present invention relates to the field of zoonotic infectious diseases, in particular to a recombinant influenza virus and its application in vaccines. The recombinant influenza virus genome is attenuated by mutation in the following gene regions: the 127-2217 base fragment of PB2; the 48-1712 base fragment of HA; the 106-1422 base fragment of NP; the 42-1346 base fragment of NA base fragment; NS 166-495 base fragment. Using the deviralization strategy to re-encode the viral genome can reduce the pathogenicity of influenza virus by about 2×10 4 times; and the recombinant influenza virus still has good immunogenicity, and the prepared vaccine can be used against homologous and heterologous viruses. Provides complete protection. |
| priorityDate | 2020-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 77.